Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has received approval from the European Commission for AVT03 (denosumab), a proposed biosimilar of Prolia® and Xgeva®. Prolia and Xgeva are widely used biologic drugs (developed by Amgen) for osteoporosis and bone-related conditions. This approval allows the company to market the biosimilar across European Union member states. The move strengthens Dr. Reddy's biosimilars portfolio in a key regulated market.
Positive for the company as it opens a large, lucrative European market for a high-demand biosimilar, potentially driving future revenue growth in the biologics segment.